113 related articles for article (PubMed ID: 14707871)
21. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival.
de Vries LH; Lodewijk L; Willems SM; Dreijerink KMA; de Keizer B; van Diest PJ; Schepers A; Bonenkamp HJ; van Engen-van Grunsven IACH; Kruijff S; van Hemel BM; Links TP; Nieveen van Dijkum EJM; van Eeden S; Valk GD; Borel Rinkes IHM; Vriens MR
Endocrine; 2018 Dec; 62(3):639-647. PubMed ID: 30128959
[TBL] [Abstract][Full Text] [Related]
22. [Clinico-prognostic analysis of course of thyroid medullary carcinoma].
Kravcheniuk AM; Reĭzin DB; Pilets'kyĭ AM; Reĭzin VI
Klin Khir; 2013 Jul; (7):31-5. PubMed ID: 24283042
[TBL] [Abstract][Full Text] [Related]
23. Polo-like kinase 1 expression in medullary carcinoma of the thyroid: its relationship with clinicopathological features.
Ito Y; Nakamura Y; Yoshida H; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Kakudo K; Miyauchi A
Pathobiology; 2005; 72(4):186-90. PubMed ID: 16127294
[TBL] [Abstract][Full Text] [Related]
24. A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness.
Hunt JL; Livolsi VA; Baloch ZW; Swalsky PA; Bakker A; Sasatomi E; Finkelstein S; Barnes EL
Hum Pathol; 2003 Apr; 34(4):375-80. PubMed ID: 12733119
[TBL] [Abstract][Full Text] [Related]
25. Analysis of risk factors for cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma.
Fan W; Xiao C; Wu F
J Int Med Res; 2018 May; 46(5):1982-1989. PubMed ID: 29569965
[TBL] [Abstract][Full Text] [Related]
26. A frequent mutation/polymorphism in tumor suppressor gene INK4B (MTS-2) in papillary and medullary thyroid cancer.
Goretzki PE; Gorelov V; Dotzenrath C; Witte J; Roeher HD
Surgery; 1996 Dec; 120(6):1081-8. PubMed ID: 8957499
[TBL] [Abstract][Full Text] [Related]
27. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
28. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C
Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027
[TBL] [Abstract][Full Text] [Related]
30. Papillary thyroid cancer: controversies in the management of neck metastasis.
Davidson HC; Park BJ; Johnson JT
Laryngoscope; 2008 Dec; 118(12):2161-5. PubMed ID: 19029855
[TBL] [Abstract][Full Text] [Related]
31. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
Machens A; Lorenz K; Dralle H
Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
[TBL] [Abstract][Full Text] [Related]
32. Surgical strategy for the treatment of medullary thyroid carcinoma.
Fleming JB; Lee JE; Bouvet M; Schultz PN; Sherman SI; Sellin RV; Friend KE; Burgess MA; Cote GJ; Gagel RF; Evans DB
Ann Surg; 1999 Nov; 230(5):697-707. PubMed ID: 10561095
[TBL] [Abstract][Full Text] [Related]
33. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
34. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
[TBL] [Abstract][Full Text] [Related]
35. Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E286-92. PubMed ID: 24297798
[TBL] [Abstract][Full Text] [Related]
36. Extrathyroidal Extension Is Associated with Compromised Survival in Patients with Thyroid Cancer.
Youngwirth LM; Adam MA; Scheri RP; Roman SA; Sosa JA
Thyroid; 2017 May; 27(5):626-631. PubMed ID: 27597378
[TBL] [Abstract][Full Text] [Related]
37. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986.
Girelli ME; Nacamulli D; Pelizzo MR; De Vido D; Mian C; Piccolo M; Busnardo B
Thyroid; 1998 Jun; 8(6):517-23. PubMed ID: 9669290
[TBL] [Abstract][Full Text] [Related]
38. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
39. Surgery for lymph node metastases of medullary thyroid carcinoma: A review.
Jin LX; Moley JF
Cancer; 2016 Feb; 122(3):358-66. PubMed ID: 26539937
[TBL] [Abstract][Full Text] [Related]
40. Detection of disseminated medullary thyroid carcinoma cells in cervical lymph nodes by cytokeratin 20 reverse transcription-polymerase chain reaction.
Weber T; Amann K; Weckauf H; Lacroix J; Weitz J; Schönfuss T; Hölting T; Klar E; Herfarth C; von Knebel Doeberitz M
World J Surg; 2002 Feb; 26(2):148-52. PubMed ID: 11865340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
